A practical approach to immunomodulatory therapy for multiple sclerosis

Physical Medicine and Rehabilitation Clinics of North America

Volumn 16, Issue 2, 2005, Pages 449-466

  Burks, Jack S ^a,b,c,d  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b Multiple Sclerosis Association of America (MSAA)   (United States)

^c Multiple Sclerosis Alliance   (United States)

^d Burks and Associates Neurology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIFIBROTIC AGENT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PARACETAMOL; PERFENIDONE; PLACEBO; STEROID; UNCLASSIFIED DRUG;

AMENORRHEA; ANXIETY; BURNING SENSATION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CHEST TIGHTNESS; CLINICAL TRIAL; COGNITION; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION RISK; INFLAMMATION; INJECTION SITE REACTION; LEUKEMIA; LIVER DYSFUNCTION; META ANALYSIS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN NECROSIS; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; POLYMERS; TREATMENT OUTCOME;

EID: 19044386771     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2005.01.007     Document Type: Review

References (67)

1. A. Compston, and A. Coles Multiple sclerosis Lancet 359 2002 1221 1231
2. P. O'Connor Key issues in the diagnosis and treatment of multiple sclerosis: an overview Neurology 59 Suppl 3 2002 S1 S33
3. J.H. Noseworthy, G. Lucchinetti, and G. Rodriguez Multiple sclerosis N Engl J Med 343 13 2000 938 952
4. S. Sriram, C.W. Stratton, and S. Yao Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis Proc Natl Acad Sci USA 92 1995 7440 7444
5. S.D. Cook, C. Rohowsky-Kochan, and S. Bansil Evidence for multiple sclerosis as an infectious disease Acta Neurol Scand 161 Suppl 1995 34 42
6. H. Simon Jack Magnetic resonance imaging in the diagnosis of multiple sclerosis, elucidation of disease course, and determining prognosis J.S. Burks K. Johnson Multiple sclerosis: diagnosis, medical management and rehabilitation 2000 Demos New York 99 126
7. B.G. Weinshenker, B. Bass, and G.P.A. Rice The natural history of multiple sclerosis: a geographically based study Brain 112 1989 133 146
8. B.G. Weinshenker, B. Bass, and G.P. Rice The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course Brain 112 1989 1419 1428
9. F.D. Lublin, and S.C. Reingold Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 4 1996 907 911
10. A.J. Thompson, X. Montalban, and F. Barkhof Diagnositc criteria for primary progressive multiple sclerosis: a position paper Ann Neurol 47 2000 831 835
11. S.A. Hawkins, and G.V. McDonnell Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors J Neurol Neurosurg Psychiatry 67 1999 148 152
12. K.P. Johnson, B.R. Brooks, and C.C. Ford Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial Mult Scler 9 6 2003 585 591
13. C. Bjartmar, G. Kidd, and R.M. Ransohoff A real-time insight into disease progression and the role of axonal injury in multiple sclerosis Arch Neurol 58 1 2001 37 39
14. T. Kuhlmann, G. Lingfeld, and A. Bitsch Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2002 2202 2212
15. B.D. Trapp, J. Peterson, and R.M. Ransohoff Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 1998 278 285
16. B. Ferguson, M.K. Matyszak, and M.M. Esiri Axonal damage in acute multiple sclerosis lesions Brain 120 1997 393 399
17. N. De Stefano, S. Narayanan, and G.S. Francis Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability Arch Neurol 58 2001 65 70
18. D.L. Arnold Magnetic resonance spectroscopy: imaging axonal damage in MS J Neuroinnunol 98 1999 2 6
19. C.F. Lucchinetti, and W. Bruck Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelization Ann Neurol 47 2000 707 717
20. M.H. Barnett, and J.W. Prineas Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 4 2004 458 468
21. L.D. Jacobs, R.W. Beck, and J.H. Simon Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis N Engl J Med 343 13 2000 898 904
22. G. Comi, M. Filippi, and F. Barkhof Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study Lancet 357 9268 2001 1576 1582
23. W. McDonald, A. Compston, and G. Edan Recommended diagnostic material for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis Ann Neurol 50 2001 121 127
24. G.P.A. Rice, E. Nicolle, and J. Lesaux Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with Interferon beta-1b Mult Scler Clin Lab Res 7 2001 S54
25. D.E. Goodkin, and the North American Study Group on Interferon Beta-1b in Secondary Progressive MS Interferon beta-1b in secondary progressive MS: clinical and MRU results of a 3-year randomized controlled trial Neurology 54 2000 2352
26. J.S. Burks INF-beta 1b (Betaseron/Betaferon) for multiple sclerosis Expert Rev Neurotherapeutics 5 2 2005 1 12
27. S. van den Noort, B. Eidelman, and K. Rammohan National Multiple Sclerosis Society (NMSS): disease management consensus statement 1998 National MS Society New York
28. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;22;58(2):169-78.
29. G.P.A. Rice, B. Incorvaia, and L. Munari Interferon in relapsing-remitting multiple sclerosis [Cochrane review] Cochrane Library 4 2001
30. L. Munari, R. Lovati, and A. Boiko Therapy with glatiramer acetate for multiple sclerosis [Cochrane review] Cochrane Library 4 2003
31. R. Arnon, and M. Sela Immunomodulation by the copolymer glatiramer acetate J Mol Recognit 16 6 2003 412 421
32. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo controlled trial Neurology 43 1993 655 661
33. The IFNB Multiple Sclerosis Study Group, and the University of British Columbia MS/MRI Analysis Group Interferon beta-1b is effective in relapsing remitting multiple sclerosis. Final outcome of the randomized controlled trial Neurology 45 1995 1277 1285
34. D.W. Paty, K.K.B. Li, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial Neurology 43 1993 662 667
35. European Study Group on Interferon Beta-1b in Secondary Progressive MS Placebo-controlled multi-center randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1998 1491 1497
36. J. Kuhle, M. Hardmeier, and J. Rio Long-term follow-up of the European Study of Interferon 1b (EUSPMS) in secondary progressive MS: predictors of treatment response Mult Scler 10 2 2004 S247
37. L. Durelli, E. Verdun, and P. Barbero Independent Comparison of Interferon (INCOMIN) Trial Study Group Every other day interferon beta-1b versus once weekly interferon beta-1a for multiple sclerosis Lancet 359 2002 1453 1460
38. P. Barbero, E. Verdun, and M. Bergui High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study J Neurol Sci 222 1-2 2004 13 19 15
39. D. Jeffery, B. Arnason, and G. Bigley MRI outcomes in relapsing-remitting multiple sclerosis patients treated with 500 mcg INFB-1b versus 250 mcg every other day: first phase of the BEYOND programme Mult Scler 10 2 2004 S244
40. L. Durelli Interferon beta-1b in multiple sclerosis: comparing two different doses (the OPTIMS Study) Mult Scler S248 2004 P603
41. R. Schapiro Adherence to interferon β: BETA Nurse Program Int J MS Care 6 2004 66
42. L. Jacobs, D. Cookfair, and R. Rudick Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Ann Neurol 39 1996 285 294
43. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
44. J.A. Cohen, G.R. Cutter, and J.S. Fischer Benefit of interferon beta-1a on MSFC progression in secondary progressive MS Neurology 59 2002 679 687
45. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;11;362(9391):1148-91.
46. H. Panitch, and D.S. Goodin Randomized comparative studies of interferon β1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496 1506
47. PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS Neurology 56 2001 1628 1636
48. PRISMS Study Group Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis Lancet 352 1998 1498 1504
49. Secondary Progressive Efficacy Trial of Recombinant Interferon Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon beta-1a in secondary progressive MS Neurology 56 2001 1496 1504
50. C. Harris, K. Billisberger, and L. Tillotson Injection site pain: interferon beta-1b versus interferon beta-1a J MS Care 6 2 2004 75 76
51. Pachner AR, Oger J, Palace J. The measurement of antibodies binding to IFN-beta in MS patients treated with IFN-beta. Neurology 2003;11;61(9 Suppl 5):S18-20.
52. L. Durelli, and A. Ricci Anti interferon antibody in multiple sclerosis. Molecular basis and there impact on clinical efficacy Frontiers Biosci 9 2004 2192 2201
53. P. Coyle Neutralizing antibodies to Interferon beta-1b in the real world Int J MS Care 6 2 2004 67
54. R.A. Rudick, N.A. Simonian, and J.A. Alam Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 50 5 1998 1266 1272
55. K.P. Johnson, B.R. Brooks, and J.A. Coher Copolymer reduces relapse rate and improves disability in RRMS Neurology 45 1995 1268 1276
56. G. Comi, M. Filippi, J.S. Wolinsky, and the European/Canadian Glatiramer Acetate Study Group European/Canadian multi-center, double-blinded, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis Ann Neurol 49 2001 290 297
57. H.H. Salama, J. Hong, and Y.C. Zang Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis Brain 1269 2003 2638 2647
58. D. Teitelbaum, T. Brenner, and O. Abramsky Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy Mult Scler 6 2004 592 599
59. N.H. Pliskin, D.P. Hamer, and D.S. Goldstein Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b Neurology 47 6 1996 1463 1468
60. J.S. Fischer, R.L. Priore, and L.D. Jacobs Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group Ann Neurol 48 6 2000 885 892
61. A. Weinstein, S.R. Schwid, and R.B. Schiffer Neuropsychologic status in multiple sclerosis after treatment with glatiramer Arch Neurol 56 3 1999 319 324
62. Wolinsky J, Coyle P, Cook S, et al. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the National Multiple Sclerosis Society. NMSS Expert Opinion Paper 2004. Available at: www.nationalmssociety.org/PRC.asp. Accessed April 4, 2005.
63. I. Pirko, and M. Rodriguez Pulsed intravenous methylprednisolone therapy in progressive MS Arch Neuro 61 7 2004 1148 1149
64. H.P. Hartung, R. Gonsette, and N. Konig Miloxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized multicenter trial Lancet 360 2002 2018 2025
65. O. Neuhaus, B.C. Kieseier, and H.P. Hartung Mitoxantrone (Novantrone) in multiple sclerosis: new insights Expert Rev Neurother 4 1 2004 17 26
66. R.A. Rudick, and A. Sandrock Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS Neurotherapeutics 4 4 2004 571 580
67. D.H. Miller, O.A. Khan, and W.A. Sheremata A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 1 2003 15 23